Glut14 Inhibitors

Glut14 Inhibitors primarily operate by obstructing the glucose transport pathway. Compounds such as Phloretin, Quercetin, and Apigenin are flavonoids that can inhibit GLUTs, including Glut14. They act by blocking the glucose transport pathway, thus reducing the transportation of glucose and indirectly inhibiting Glut14. Cytochalasin B, a potent inhibitor of actin polymerization, can influence glucose transportation by disrupting the actin cytoskeleton, a component necessary for GLUT translocation. This disruption indirectly leads to the inhibition of Glut14. Meanwhile, Genipin, a natural crosslinker that can inhibit uncoupling proteins like UCP2, can indirectly affect the function of Glut14, given the interaction between Glut14 and UCP2.

Simultaneously, Glut14 inhibitors may target the glucose transport pathway through competitive inhibition among the GLUT family members. Inhibitors such as STF-31, WZB117, BAY-876, and Ritonavir inhibit other GLUTs, notably GLUT1 and GLUT4, reducing glucose transport and creating a competitive environment among the GLUT family members. This competition indirectly leads to the inhibition of Glut14. Similarly, Fasentin, which sensitizes cells to apoptosis induced by FasL and inhibits GLUT1, could indirectly inhibit Glut14 by creating a competitive environment among the GLUT family members. Lastly, Pf-06424439 and Azaserine inhibit key enzymes and pathways in glucose metabolism, leading to reduced glucose uptake and the indirect inhibition of Glut14.